{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:28:16Z","timestamp":1787099296394,"version":"build-2736575974"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":69,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-026-05082-x","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:33:36Z","timestamp":1781195616000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of low-dose combination urate-lowering agent therapy versus standard-dose monotherapy in patients with hyperuricemia and\/or gout: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"27","author":[{"given":"Takashi","family":"Sakaguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisatomi","family":"Arima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taichi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reimi","family":"Tsurusawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamami","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumi","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Masutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikara","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Funakoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Nagamitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"5082_CR1","doi-asserted-by":"publisher","first-page":"204201882412272","DOI":"10.1177\/20420188241227295","volume":"15","author":"T Han","year":"2024","unstructured":"Han T, Chen W, Qiu X, Wang W. Epidemiology of gout - global burden of disease research from 1990 to 2019 and future trend predictions. Ther Adv Endocrinol Metab. 2024;15:20420188241227295. https:\/\/doi.org\/10.1177\/20420188241227295.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"5082_CR2","unstructured":"Committee for the preparation of guidelines for the management of hyperuricemia and gout, Japanese society of gout and nucleic acid metabolism. Guidelines for the management of hyperuricemia and gout. 2021;114\u201317. Tokyo: Japanese society of Gout and Uric & Nucleic Acids."},{"issue":"9","key":"5082_CR3","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.3390\/jcm11092468","volume":"11","author":"Y Lee","year":"2022","unstructured":"Lee Y, Hwang J, Desai SH, Li X, Jenkins C, Kopp JB, et al. Efficacy of xanthine oxidase inhibitors in lowering serum uric acid in chronic kidney disease: a systematic review and meta-analysis. J Clin Med. 2022;11(9):2468. https:\/\/doi.org\/10.3390\/jcm11092468.","journal-title":"J Clin Med"},{"issue":"8","key":"5082_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11926-018-0760-2","volume":"20","author":"GG Graham","year":"2018","unstructured":"Graham GG, Stocker SL, Kannangara DRW, Day RO. Predicting response or non-response to urate-lowering therapy in patients with gout. Curr Rheumatol Rep. 2018;20(8):47. https:\/\/doi.org\/10.1007\/s11926-018-0760-2.","journal-title":"Curr Rheumatol Rep"},{"issue":"10","key":"5082_CR5","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, FitzGerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. American College of Rheumatology guidelines for management of gout. Part, 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431\u201346.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"5082_CR6","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72(6):744\u201360.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7404","key":"5082_CR7","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1136\/bmj.326.7404.1427","volume":"326","author":"MR Law","year":"2003","unstructured":"Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326(7404):1427. https:\/\/doi.org\/10.1136\/bmj.326.7404.1427.","journal-title":"BMJ"},{"key":"5082_CR8","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"key":"5082_CR9","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","DOI":"10.1136\/bmj.l4898"},{"issue":"1","key":"5082_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12(1):55\u201361. https:\/\/doi.org\/10.1002\/jrsm.1411. Epub 2020 May 6.","journal-title":"Res Synth Methods"},{"issue":"5","key":"5082_CR11","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s10067-019-04893-8","volume":"39","author":"YJ Lin","year":"2020","unstructured":"Lin YJ, Lin SY, Lin CH, Wang ST, Chang SS. Evaluation of urate-lowering therapy in hyperuricemia patients: a systematic review and Bayesian network meta-analysis of randomized controlled trials. Clin Rheumatol. 2020;39(5):1633\u201348. https:\/\/doi.org\/10.1007\/s10067-019-04893-8.","journal-title":"Clin Rheumatol"},{"issue":"23\u201324","key":"5082_CR12","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.drudis.2011.10.003","volume":"16","author":"J L\u00f6tsch","year":"2011","unstructured":"L\u00f6tsch J, Geisslinger G. Low-dose drug combinations along molecular pathways could maximize therapeutic effectiveness while minimizing collateral adverse effects. Drug Discov. Today Today. 2011;16(23\u201324):1001\u201306. https:\/\/doi.org\/10.1016\/j.drudis.2011.10.003.","journal-title":"Drug Discov. Today Today"},{"issue":"4","key":"5082_CR13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/s0895-7061(99)00112-0","volume":"12","author":"JM Neutel","year":"1999","unstructured":"Neutel JM. Low-dose antihypertensive combination therapy: its rationale and role in cardiovascular risk management. Am J Hypertens. 1999;12(4):73\u201379. https:\/\/doi.org\/10.1016\/s0895-7061(99)00112-0.","journal-title":"Am J Hypertens"},{"issue":"10287","key":"5082_CR14","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/S0140-6736(21)00569-9","volume":"397","author":"N Dalbeth","year":"2021","unstructured":"Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. Lancet. 2021;397(10287):1843\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(21)00569-9. Epub 2021 Mar 30.","journal-title":"Lancet"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-05082-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05082-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05082-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:07:45Z","timestamp":1787098065000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-05082-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5082"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-05082-x","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"26 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study is a systematic review and meta-analysis of previously published studies involving no direct human participants. Ethical approval was waived as no individual data were collected. This study was conducted in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable, as this study is a systematic review and meta-analysis of previously published data.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"488"}}